
Results
9
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
9 companies
AbbVie
Market Cap: US$449.6b
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
ABBV
US$253.38
7D
2.2%
1Y
37.1%
Merck
Market Cap: US$314.9b
Operates as a healthcare company worldwide.
MRK
US$124.40
7D
0.3%
1Y
56.9%
Travere Therapeutics
Market Cap: US$5.3b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$55.47
7D
-1.5%
1Y
250.6%
Sotera Health
Market Cap: US$5.1b
Provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$17.42
7D
-4.1%
1Y
58.2%
Mesa Laboratories
Market Cap: US$541.1m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$96.67
7D
1.8%
1Y
42.2%
SIGA Technologies
Market Cap: US$246.7m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.48
7D
-3.6%
1Y
-49.2%
Waters
Market Cap: US$36.2b
Provides analytical workflow solutions in Asia, the Americas, and Europe.
WAT
US$357.54
7D
-4.2%
1Y
26.9%
BioLife Solutions
Market Cap: US$1.4b
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
BLFS
US$29.09
7D
3.5%
1Y
40.1%
Repligen
Market Cap: US$8.3b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$145.49
7D
0.4%
1Y
26.7%